1448754-39-9Relevant academic research and scientific papers
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties
Zablocki, Jeff A.,Elzein, Elfatih,Li, Xiaofen,Koltun, Dmitry O.,Parkhill, Eric Q.,Kobayashi, Tetsuya,Martinez, Ruben,Corkey, Britton,Jiang, Haibo,Perry, Thao,Kalla, Rao,Notte, Gregory T.,Saunders, Oliver,Graupe, Michael,Lu, Yafan,Venkataramani, Chandru,Guerrero, Juan,Perry, Jason,Osier, Mark,Strickley, Robert,Liu, Gongxin,Wang, Wei-Qun,Hu, Lufei,Li, Xiao-Jun,El-Bizri, Nesrine,Hirakawa, Ryoko,Kahlig, Kris,Xie, Cheng,Li, Cindy Hong,Dhalla, Arvinder K.,Rajamani, Sridharan,Mollova, Nevena,Soohoo, Daniel,Lepist, Eve-Irene,Murray, Bernard,Rhodes, Gerry,Belardinelli, Luiz,Desai, Manoj C.
, p. 9005 - 9017 (2016/10/22)
Late sodium current (late INa) is enhanced during ischemia by reactive oxygen species (ROS) modifying the Nav 1.5 channel, resulting in incomplete inactivation. Compound 4 (GS-6615, eleclazine) a novel, potent, and selective inhibitor of late INa, is currently in clinical development for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia-ventricular fibrillation (VT-VF). We will describe structure-activity relationship (SAR) leading to the discovery of 4 that is vastly improved from the first generation late INa inhibitor 1 (ranolazine). Compound 4 was 42 times more potent than 1 in reducing ischemic burden in vivo (S-T segment elevation, 15 min left anteriorior descending, LAD, occlusion in rabbits) with EC50 values of 190 and 8000 nM, respectively. Compound 4 represents a new class of potent late INa inhibitors that will be useful in delineating the role of inhibitors of this current in the treatment of patients.
